Cavalier King Charles Spaniel Gene Variants Raise Heart Disease Risk 52-Fold

A 52-Fold Risk: Researchers Pinpoint Gene Combination Behind Cavalier Heart Disease

Cavalier King Charles Spaniels carrying two specific gene variants face a 52.5 times higher risk of developing myxomatous mitral valve disease (MMVD), according to new research from the University of Copenhagen published in Animal Genetics. The finding comes from whole genome sequencing of 19 dogs and validation in 250 more, and it offers breeders a possible tool to finally reduce a disease that affects well over half of aging Cavaliers. Similar genetic detective work is underway for epilepsy in Petit Basset Griffon Vendéens, where the search is proving harder but still informative.

Why the Cavalier’s Heart Fails: The Genetics of MMVD

MMVD is the most common heart disease in dogs. The mitral valve’s leaflets thicken and bulge, allowing blood to leak backward into the left atrium — a murmur that, over years, can progress to congestive heart failure. Cavaliers develop the disease earlier and more severely than almost any other breed, which is why researchers have long suspected a strong genetic component. For more background on how genes shape disease risk in purebred dogs, see our companion article on dog breed genetics.

Lene Holm Olsen and colleagues at the University of Copenhagen, working with Häggström’s group at the Swedish University of Agricultural Sciences, had previously identified disease-associated regions on chromosomes 13 and 14. In the new study, they sequenced the entire genomes of 9 severely affected Cavaliers — dogs with mitral regurgitation before age 4.5 or heart failure at any age — and 10 healthy controls aged over 8 with no or mild regurgitation.

That sequencing revealed more than 2,000 genetic variants in the two candidate regions. Filtering with Ensembl Variant Effect Predictor narrowed the list to 18 variants with plausible functional effects. Genotyping these in 250 dogs produced four strongly associated variants (p-values between 2.03×10⁻⁸ and 4.20×10⁻⁶), including a nonsynonymous variant in HYAL4, a gene involved in hyaluronan breakdown, and the two standouts: a 39 base-pair insertion in LMOD2 and a splice-site variant in a long noncoding RNA (lncRNA) on chromosome 13.

The biology makes sense. LMOD2 helps build the actin cytoskeleton of heart muscle cells, while lncRNAs regulate when and how strongly other genes are expressed. A splice-site variant — one that disrupts how RNA is cut and joined before protein synthesis — can silence regulatory RNA entirely. Neither variant alone tells the full story; dogs homozygous for both risk alleles showed an odds ratio of 52.5 (95% CI: 8.8–1023.8) compared with dogs carrying neither.

The Epilepsy Hunt in Petit Basset Griffon Vendéens: A Harder Puzzle

Genetic sleuthing does not always produce clean answers. A University of Copenhagen team led by Tessa Deschain ran the first genome-wide association study for idiopathic epilepsy in Petit Basset Griffon Vendéens, comparing 23 affected dogs with 30 unaffected ones across 170,000 SNPs.

Three suggestive loci emerged — on chromosomes 13, 24, and 35 — near genes considered strong candidates for seizure disorders. But when the researchers sequenced those genes’ exons, no disease-causing variation appeared. The likely explanation: the causal variant sits in regulatory DNA outside the sequenced exons, or the disease involves variants the study lacked the statistical power to detect with just 53 dogs.

This result is not a failure. It narrows the search space for future studies and illustrates a central lesson of canine genetics: complex breed diseases rarely trace to a single broken gene. They arise from combinations of variants, each adding risk, exactly as seen with the Cavalier heart findings.

What This Means for Breeders and Owners

The Cavalier findings could change breeding practice — with caveats. The authors are explicit that validation in an independent cohort is needed before a commercial test makes sense. Because the risk alleles are likely widespread in the breed, removing every carrier from breeding could shrink the gene pool and worsen other health problems. A realistic approach would prioritize pairings that avoid producing puppies homozygous for both risk alleles, gradually reducing disease frequency over generations.

For owners, the genetics do not replace vigilance. If you have a Cavalier, ask your veterinarian about annual auscultation — listening for a murmur — starting around age 5, since early detection and treatment of MMVD can slow its progression. Our coverage of canine heart disease research covers current management strategies in more detail.

Frequently Asked Questions

Can I test my Cavalier King Charles Spaniel for these heart disease genes?

Not yet. The researchers emphasize that the LMOD2/lncRNA finding must be validated in an independent group of dogs before a breeding DNA test can be released.

Does having the risk gene variants mean my dog will definitely get heart disease?

No. Even homozygosity for both risk alleles produced an odds ratio of 52.5 — a very high risk, but not certainty, and environmental and other genetic factors also contribute.

Do Petit Basset Griffon Vendéens have a genetic test for epilepsy?

No. The 2021 study identified candidate loci on chromosomes 13, 24, and 35, but no causative variant has been found, so no test currently exists.

Why do purebred dogs have so many breed-specific diseases?

Generations of selection within closed populations concentrates both desirable traits and harmful variants, which is why conditions like MMVD in Cavaliers and epilepsy in Petit Basset Griffon Vendéens run strongly in certain breeds.

In under a decade, veterinary genetics has moved from mapping vague disease “regions” to identifying specific interacting variants with quantified risk. For breeds built around small founder populations, that precision may be the most effective welfare tool available — provided breeders use it to manage risk rather than eliminate carriers wholesale.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42708524/
https://pubmed.ncbi.nlm.nih.gov/34383319/
https://pubmed.ncbi.nlm.nih.gov/33983928/
https://pubmed.ncbi.nlm.nih.gov/33890524/
https://pubmed.ncbi.nlm.nih.gov/33243158/